Influence of co-stimulatory molecules B7-H4 expression on the prognosis of patients with gastric cancer treated with cytokine-induced killer cells adoptive immunotherapy.
- Author:
Jing-ting JIANG
1
;
Chang-ping WU
;
Yue-ping SHEN
;
Lu ZHENG
;
Jun WU
;
Mei JI
;
Bin XU
;
Lu-jun CHEN
;
Yu-gang WU
;
Xiao ZHENG
;
Yi-bei ZHU
;
Bin-feng LU
;
Xue-guang ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; B7-1 Antigen; metabolism; Cytokine-Induced Killer Cells; Disease-Free Survival; Female; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Prognosis; Retrospective Studies; Stomach Neoplasms; diagnosis; metabolism; therapy; V-Set Domain-Containing T-Cell Activation Inhibitor 1
- From: Chinese Journal of Gastrointestinal Surgery 2010;13(5):366-370
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the influence of co-stimulatory molecules B7-H4 expression on prognosis of gastric cancer patients treated by cytokine-induced killer cells (CIK cells) adoptive immunotherapy.
METHODSClinical data of 156 cases of gastric cancer patients were retrospectively analyzed. Patients were divided into chemotherapy group(n=81) and chemotherapy combined with CIK cell therapy group(n=75). B7-H4 expression was detected in the surgical specimens of gastric cancer patients by immunohistochemistry assay. Disease-free survival was compared between the chemotherapy group and the CIK group at different expression levels of B7-H4.
RESULTSThe difference was not statistically significant in all clinical and pathological data between the chemotherapy group and the CIK treatment group (P>0.05). The postoperative median tumor-free survival in two groups was 18.0 and 45.0 months, respectively, and the difference was statistically significant (chi(2)=11.631, P=0.001). The postoperative median survival time was 27.0 and 49.0 months, respectively, and the difference was statistically significant (chi(2)=10.907, P=0.001). In 86 patients with low B7-H4 expression, the median tumor-free survival time was 32.0 and 62.0 months, respectively, and the difference was statistically significant (chi(2)=4.663,P=0.03). In 70 patients with high B7-H4 expression, the median tumor-free survival time was 11.0 and 18.0 months, respectively, and the difference was statistically significant (chi(2)=11.971, P=0.001).
CONCLUSIONThe median tumor-free survival time of patients with gastric cancer may be further improved by chemotherapy combined with CIK cell therapy, regardless of the level of B7-H4 expression.
